February 20, 2013Open Access

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

Key Points

Key points are not available for this paper at this time.

Abstract

Ruxolitinib-treated patients achieved clinically meaningful improvements in myelofibrosis-related symptoms and QoL, but patients receiving placebo reported worsening of symptoms and other PROs.

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Mesa et al. (Wed,) studied this question.

synapsesocial.com/papers/69dff21c2c052bbf722554c2 https://doi.org/https://doi.org/10.1200/jco.2012.44.4489

Demander à l'IA

Bookmark

View Full Paper